Companies / Croatia
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Lagging Behind Regional Peers
July 2007 | BMI ViewSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
The Croatian market is small and behind many of its regional neighbours, including Hungary, despite its relatively advanced status. At more than 70% by value, generics - comprising mostly relatively expensive branded generics - meet the bulk of demand for pharmaceuticals, with the segment continuing to be boosted by healthcare debts, cost-containment initiatives and the support for the strong domestic generics industry in the face of distinct intellectual property (IP) deficiencies.